Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × bexmarilimab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 22 pembrolizumab 19 Cisplatin 15 Nivolumab 14 Fluorouracil 14 Capecitabine 13 Leucovorin 12 Carboplatin 12 Bevacizumab 12 Oxaliplatin 11 Radiotherapy 10 Lenalidomide 10 Dexamethasone 10 fludarabine 9 avelumab 9 Taxes 9 Rituximab 9 Gemcitabine 9 Radiosurgery 8 Azacitidine 8 venetoclax 7 fludarabine phosphate 7 Irinotecan 7 Ipilimumab 7 Docetaxel 7 ALT-803 7 Omacor 6 Melphalan 6 Interleukin-2 6 Etoposide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡